AC Immune and Lilly reload their Alzheimer’s bet

Same partnership, bigger ambitions

AC Immune is back in the lab-and-legal-documents blender with Eli Lilly. The two companies amended their 2018 licensing and collaboration agreement to expand development work on new lead tau morphomer candidates plus backup compounds for Alzheimer’s.

Why investors should care

This isn’t just another biotech handshake photo-op. AC Immune gets roughly $12.68 million now, but the real headline is the milestone ladder: more than $2.16 billion in potential payments if the program keeps advancing. That kind of number is biotech’s version of a jackpot sign — flashing brightly, but still a long walk from the casino floor.

What changed?

The amendment suggests Lilly is still interested in AC Immune’s tau-focused platform, which matters because tau remains one of the major targets in the Alzheimer’s hunt. In plain English: Lilly is not walking away; it’s leaning in and giving the program a tune-up.

Big picture

For AC Immune, this is another reminder that partnership value can matter as much as trial data. For investors, the story is less about a quick revenue pop and more about whether this collaboration keeps building credibility — and optionality — around one of biotech’s toughest prize fights.